Bhalchandra Kawdikar: FDA Approves Rusfertide for Polycythemia Vera
Bhalchandra Kawdikar, Vice President International Marketing at Edge Pharma (merchant Exporter), shared a post on LinkedIn:
”FDA Approves MIMRYLO Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Aug 28, 2026.
Why it matters: New hope in reducing the risk of life-threatening conditions due to chronic blood cancer.
PV is a chronic blood cancer. In PV RBC’s are overproduced, increasing the blood viscosity.
This can result in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism.
Takeda’s Mimrylo (Rusfertide) is a first-in-class SC Inj. It mimics the action of hepcidin, (a natural hormone that regulates iron homeostasis and erythrocytosis).
By targeting the underlying mechanism of iron dysregulation MIMRYLO aims reduces excess RBC production and helps maintain hematocrit control.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge